Dr. Marcel Hungs, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 354
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MN license 52463 -
Sleep Medicine (Psychiatry & Neurology) Physician
MN license 52463
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Park Nicollet Methodist Hospital Saint Louis PArk, MN
- Regions Hospital Saint PAul, MN
- Lakeview Memorial Hospital Stillwater, MN
- Amery Hospital & Clinic Amery, WI
Medical groups
- Park Nicollet Clinic (1,787 clinicians)
- Group Health Inc (1,638 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 354
- Services billed
- 735
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 241 | 198 |
| New patient office or other outpatient visit, 45-59 minutes | 91 | 91 |
| Established patient office or other outpatient visit, 40-54 minutes | 45 | 43 |
| Insertion of needle into vein for collection of blood sample | 35 | 34 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 16 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 13 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 13 | 12 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Saint PAul, MN | 369 |
| Gabapentin Other prescribers in Saint PAul, MN | 317 |
| Memantine Hcl Other prescribers in Saint PAul, MN | 278 |
| Levetiracetam Other prescribers in Saint PAul, MN | 199 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Saint PAul, MN | 142 |
| Ropinirole Hcl Other prescribers in Saint PAul, MN | 127 |
| Lamotrigine Other prescribers in Saint PAul, MN | 107 |
| Pregabalin Other prescribers in Saint PAul, MN | 79 |
| Primidone Other prescribers in Saint PAul, MN | 69 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in Saint PAul, MN | 66 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $200,774 in research payments for these studies, mostly to the institutions running them.
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
UCB SA · Completed · NCT04867616 - Study name not reported
Novo Nordisk As - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c. - A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Biogen, Inc. - A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06929273
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.